检索结果-南通市图书馆

World Journal of Gastroenterology 2007年第3期13卷 470-473页

作者： yusuke koizumi Hirozumi Obata Akinori Hara Takashi Nishimura Kenichiro Sakamoto Yoshihide Fujiyama Department of Gastroenterology and Hematology Shiga University of Medical Science Otsu Japan Department of Medicine Saiseikai Suita Hospital Suita Japan Department of Surgery Saiseikai Suita Hopspital Suita Japan

A 34-year-old female complaining of abdominal fullness was diagnosed as scirrhous gastric cancer （type 4＇） with peritonitis carcinomatosa in July 2002. A combined chemotherapy regimen was selected to control massive ascites; TS-1 80 mg/m^2 was given orally on d 1-14, 22-35, and paclitaxel 50 mg/m^2 was administered intravenously on d 1, 8, 22 and 29. After 2 courses of this regimen, the primary tumor was markedly reduced, and ascites completely vanished. Alopecia （grade 1, since d 30）, leukocytopenia （grade 2, on d 34） and anemia （grade 2, on d 34） were the only adverse events throughout the following courses. The chemotherapy was effective for 28 mo, and then it was discontinued upon the patient＇s own request, and she survived for 36 mo after diagnosis.

关键词： TS-1 Paclitaxel Scirrhous gastric cancer Peritonitis carcinomatosa

Is Dose Adjustment Based on Several Factors of Body Size Descriptors Effective for Prevention of Thrombocytopenia by Linezolid Therapy in Hemodialysis Patients?

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Pharmacology & Pharmacy 2016年第10期7卷 417-423页

作者： Hideo Kato Mao Hagihara Yuka Yamagishi Yukihiro Hamada Jun Hirai Naoya Nishiyama yusuke koizumi Katsuhiko Matsuura Hiroshige Mikamo Department of Infection Control and Prevention Aichi Medical University School of Medicine Nagakute Japan Department of Pharmacy Aichi Medical University School of Medicine Nagakute Japan

Previous study suggested that low body weight was one of the risk factors of thrombocytopenia induced by linezolid in non-hemodialysis patients. However, there have been little investigations for the linezolid-induced thrombocytopenia in hemodialysis patients. This study was to evaluate the association between several factors of body size descriptors and thrombocytopenia in hemodialysis-patients. No factor of body size descriptors showed significant correlation with linezolid-induced thrombocytopenia (patients with thrombocytopenia vs patients without thrombocytopenia: body weight;60.0 kg vs 55.3 kg, p = 0.82: body mass indices;21.1 kg/m2 vs 21.2 mg/m2, p = 0.44: ideal body weight;61.2 kg vs 59.5 kg, p = 0.21: lean body weight;50.1 kg vs 45.7 kg, p = 0.64: dosage amount;20.0 mg/kg vs 21.7 mg/kg, p = 0.74: body surface area;1.65 m2 vs 1.54 m2, p = 0.43). There were not significant differences in the body size descriptors between linezolid therapy for more than 14 days and for less than 13 days (more than 14 days vs less than 13 days: body weight;53.5 kg vs 56.8 kg, p = 0.75: body mass indices;20.9 kg/m2 vs 21.1 mg/m2, p = 0.47: ideal body weight;60.3 kg vs 59.9 kg, p = 0.17: lean body weight;44.3 kg vs 47.7 kg, p = 0.56: dosage amount;22.4 mg/kg vs 21.1 mg/kg, p = 0.67: body surface area;1.51 m2 vs 1.59 m2, p = 0.37). Our data suggested that dosage adjustment of linezolid based on body weight was not recommended in hemodialysis-patients.

关键词： Linezolid Thrombocytopenia Body Weight

Use of Cryopreserved Osteogenic Matrix Cell Sheets for Bone Reconstruction

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Stem Cell Discovery 2016年第1期6卷 13-23页

作者： Tomohiko Kura Manabu Akahane Takamasa Shimizu Yoshinobu Uchihara Yasuaki Tohma yusuke Morita Munehisa koizumi Kenji Kawate Yasuhito Tanaka Department of Orthopedic Surgery Nara Medical University School of Medicine Kashihara Japan Department of Public Health Health Management and Policy Nara Medical University School of Medicine Kashihara Japan Departmentof Biomedical Engineering Doshisha University Kyotanabe Japan Department of Artificial Joint and Regenerative Medicine Nara Medical University Kashihara Japan

Skeletal diseases, such as nonunion and osteonecrosis, are now treatable with tissue engineering techniques. Single cell sheets called osteogenic matrix cell sheets (OMCSs) grown from cultured bone marrow-derived mesenchymal stem cells show high osteogenic potential;however, long preparation times currently limit their clinical application. Here, we report a cryopreservation OMCS transplantation method that shortens OMCS preparation time. Cryopreserved rat OMCSs were prepared using slow- and rapid-freezing methods, thawed, and subsequently injected scaffold-free into subcutaneous sites. Rapid- and slow-frozen OMCSs were also transplanted directly to the femur bone at sites of injury. Slow-freezing resulted in higher cell viability than rapid freezing, yet all two cryopreservation methods yielded OMCSs that survived and formed bone tissue. In the rapid- and slow-freezing groups, cortical gaps were repaired and bone continuity was observed within 6 weeks of OMCS transplantation. Moreover, while no significant difference was found in osteocalcin expression between the three experimental groups, the biomechanical strength of femurs treated with slow-frozen OMCSs was significantly greater than those of non-transplant at 6 weeks post-injury. Collectively, these data suggest that slow-frozen OMCSs have superior osteogenic potential and are better suited to produce a mineralized matrix and repair sites of bone injury.

关键词： Bone Marrow Stromal Cell Cryopreservation Cell Sheet Injectable Bone Bone Reconstruction

Olmesartan for non-alcoholic steatohepatitis complicated with hypertension: An open-label study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Open Journal of Gastroenterology 2013年第2期3卷 128-133页

作者： Hisashi Hidaka Makoto Ohbu Yasuhiro Matsumoto Tsutomu Minamino Juichi Takada Yoshiaki Tanaka yusuke Okuwaki Masaaki Watanabe Takahide Nakazawa Akitaka Shibuya Wasaburo koizumi Department of Gastroenterology Kitasato University School of Medicine Sagamihara Kanagawa Japan Department of Pathology Kitasato University School of Allied Health Science Sagamihara Kanagawa Japan

Aim: We evaluated the long-term effects of olmesartan, an angiotensin type 1 receptor blocker, in patients with non-alcoholic steatohepatitis (NASH) complicated with hypertension. Methods: All patients were given a standard calorie diet and exercise counseling more than 3 months before the treatment. Seven patients with NASH received olmesartan treatment for 1 year. Liver biopsy, clinical parameters and blood markers of hepatic fibrosis, including serum hyaluronic acid, type IV collagen, and procollagen III N-terminal propeptide levels, were also examined at the beginning and the end of the study. Results: The median dose of the final administration was 20 mg (range, 10 - 40 mg). Olmesartan reduced MAP by –11.3 ± 13.0% (P = 0.046) after 1 year. In the laboratory data, serum AST, ALT, and ferritin significantly decreased after a year of administration (AST, 62 ± 24 vs. 39 ± 20 IU/L, P = 0.018;ALT, 106 ± 79 vs. 55 ± 35 IU/L, P = 0.043;ferritin, 323.8 ± 252.8 vs. 202.3 ± 194.1 ng/ml, P = 0.028). Furthermore, fasting glucose significantly decreased. However, transforming growth factor-beta1, the serum concentration of the fibrosis markers, and all histological features were unchanged at the end of the study. No side effects of the treatment were noted at any time during the study. Conclusion: Olmesartan significantly reduced blood pressure, fasting glucose, aminotransferase, and serum ferritin but could not suppress the hepatic fibrosis markers or histological features after 1 year. Therefore, olmesartan is advisable only for its anti-inflammatory effect in patients with NASH-complicated hypertension.

关键词： Angiotensin Type 1 Receptor Blocker Hepatic Fibrosis TGF-Beta1

Usefulness of serum lipase for early diagnosis of post-endoscopic retrograde cholangiopancreatography pancreatitis

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal Endoscopy 2019年第9期11卷 477-485页

作者： Masayoshi Tadehara Kosuke Okuwaki Hiroshi Imaizumi Mitsuhiro Kida Tomohisa Iwai Hiroshi Yamauchi Toru Kaneko Rikiya Hasegawa Eiji Miyata yusuke Kawaguchi Hironori Masutani Wasaburo koizumi Department of Gastroenterology Kitasato University School of Medicine

BACKGROUND Post-endoscopic retrograde cholangiopancreatography(ERCP)pancreatitis(PEP)is new onset acute pancreatitis after *** complication is sometimes *** such,PEP should be diagnosed early so that therapeutic interventions can be carried *** lipase(s-Lip)is useful for diagnosing acute ***,its usefulness for diagnosing PEP has not been sufficiently *** This study aimed to retrospectively examine the usefulness of s-Lip for the early diagnosis of *** We retrospectively examined 4192 patients who underwent ERCP at our two hospitals over the last 5 *** primary outcomes were a comparison of the areas under the receiver operating characteristic(ROC)curves(AUCs)of s-Lip and serum amylase(s-Amy),s-Lip and s-Amy cutoff values based on the presence or absence of PEP in the early stage after ERCP via ROC curves,and the diagnostic properties[sensitivities,specificities,positive predictive values(PPV),and negative predictive value(NPV)]of these cutoff values for PEP *** Based on the eligibility and exclusion criteria,804 cases were *** the entire course,PEP occurred in 78 patients(9.7%).It occurred in the early stage after ERCP in 40 patients(51.3%)and in the late stage after ERCP in 38 patients(48.7%).The AUCs were 0.908 for s-Lip[95%confidence interval(CI):0.880-0.940,P<0.001]and 0.880 for s-Amy(95%CI:0.846-0.915,P<0.001),indicating both are useful for early *** comparing the AUCs,s-Lip was found to be significantly more useful for the early diagnosis of PEP than s-Amy(P=0.023).The optimal cutoff values calculated from the ROC curves were 342 U/L for s-Lip(sensitivity,0.859;specificity,0.867;PPV,0.405;NPV,0.981)and 171 U/L for s-Amy(sensitivity,0.859;specificity,0.763;PPV,0.277;NPV,0.979).CONCLUSION S-Lip was significantly more useful for the early diagnosis of *** s-Lip after ERCP could help diagnose PEP earlier;hence,therapeutic interventions can be provided earlier.

关键词： Endoscopic retrograde cholangiopancreatography Post-endoscopic retrograde cholangiopancreatography pancreatitis Pancreatitis Lipase Amylase